ClinicalTrials.gg
CompletedNCT04654897Updated Oct 28, 2021

Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects

A Phase 1 interventional study of [14C]-NT-814 in Healthy, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This is a single centre, open-label, non-randomised study to assess the mass balance recovery, absorption, metabolism, and excretion of a single oral dose of [14C]-NT-814 in healthy male subjects. It is planned to enrol 6 subjects. Each subject will receive a single dose of 120 mg [14C] NT-814 containing not more than (NMT) 5.6 megabecquerel (MBq) [14C], administered as an oral suspension in the fasted state. Subjects will remain in the study until a mass balance cumulative recovery of >90% and \<1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 hour periods.

Read the detailed description

Subjects will undergo preliminary screening procedures for the study up to 28 days before [14C]-NT-814 administration. Subjects will be admitted in the evening on the day prior to [14C]-NT-814 administration (Day -1) at which time further screening procedures will be undertaken to confirm eligibility. Subjects will be dosed in the morning of Day 1 following an overnight fast of a minimum of 8 hours.

It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90% and \<1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 hour periods.

This may result in the subjects being discharged as a group prior to completion of the planned residency period. If the mass balance discharge criteria are achieved during the planned residency period, collection of all samples (blood, urine, and faeces) will be stopped and subjects will undergo discharge assessments. If mass balance discharge criteria have not been met by all subjects by Day 15, the residency period for the subjects not achieving the mass balance discharge criteria may be extended up to a maximum of 48 hours (i.e., up to Day 17). Blood, urine and faeces will be collected for 24 hour intervals during the extended residency period whilst the subjects are resident in the clinic.

If the mass balance discharge criteria are still not met by Day 17, subjects will enter a home collection phase during which they will collect 24-hour urine and faeces on a daily basis up until Day 24 (or until the criteria are met) and then on a weekly basis starting on Day 31 (until criteria met or Day 45 reached). During the period of weekly collection, mass balance cumulative recovery will be estimated by means of interpolation.

No additional collections will be performed for subjects who still do not meet the criteria on Day 45. Subjects entering the home collection phase will return on Day 19 ± 12 hours for blood sample collection. Discharge safety assessments will be performed at the time of actual discharge from the clinical unit.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males
  • Aged 30 to 65 years inclusive at the time of signing .
  • (BMI) of 18.0 to 35.0 kg/m\^2, inclusive, as measured at screening.
  • Must be able to understand the requirement of the study and be willing to participate in the whole study.
  • Must have regular bowel movements (i.e., usual stool production of ≥1 and ≤3 stools per day).
  • Must provide written informed consent.
  • Must agree to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1.
  • Subjects who are, or are immediate family members of, a study site or Sponsor employee.
  • Evidence of current SARS-CoV-2 infection.
  • History of any drug or alcohol abuse in the past 2 years.
  • Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type).
  • A confirmed positive alcohol breath test at screening or admission.
  • Current smokers and those who have smoked within the last 12 months.
  • A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  • Subjects with pregnant or lactating partners.
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017 [7], shall participate in the study.
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator or delegate at screening.
  • abnormal clinical chemistry, haematology or urinalysis as judged by the Investigator.
  • Subjects with biochemically verified Gilbert's Syndrome are allowed.
  • Subjects with a presence of any of the following at screening, confirmed by a repeat test: , alanine aminotransferase or, gamma glutamyl transferase above the .
  • Confirmed positive drugs of abuse test result.
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) antibody results.
  • Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<80 mL/min using the Cockcroft-Gault equation.
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or GI disease, neurological or psychiatric disorder, as judged by the Investigator.
  • Serious adverse reaction or serious to any drug or the formulation .
  • Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator.
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood.
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) in the 14 days before IMP administration.
  • History of GI surgery (with the exception of appendectomy unless it was performed within the previous 3 months).
  • Acute diarrhoea or constipation in the 7 days before the predicted Day 1.
  • Failure to satisfy the Investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Elinzanetant (NT-814, BAY3427080)

    Subjects received a single dose of 120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) orally.

    Drug: [14C]-NT-814

Interventions

  • 120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].

06

What researchers measure

Primary outcomes

  1. Mass Balance Recovery of Total Radioactivity: CumAe(Urine)

    CumAe(Urine): cumulative amount of Total Radioactivity (TR) excreted in urine.

    Time frame: Day 45 (maximum)

  2. Mass Balance Recovery of Total Radioactivity: Cum%Ae(Urine)

    Cum%Ae(Urine): cumulative amount of TR excreted in urine expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  3. Mass Balance Recovery of Total Radioactivity: CumAe(Faeces)

    CumAe(Faeces): cumulative amount of TR excreted in faeces.

    Time frame: Day 45 (maximum)

  4. Mass Balance Recovery of Total Radioactivity: Cum%Ae(Faeces)

    Cum%Ae(Faeces): cumulative amount of TR excreted in faeces expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  5. Mass Balance Recovery of Total Radioactivity: CumAe(Total)

    CumAe(Total): cumulative amount of TR excreted in urine and faeces combined. The radioactivity associated with toilet tissue was also determined, and the results were reported for each subject as a single value for the whole collection period only and included in the calculation of total Ae and % of dose recovered. The data reported for total calculations excluded toilet tissue data for the 0 - 6 hours post-dose to 0 - 456 hours post-dose collection intervals and included toilet tissue data for the 0 - 480 hours post-dose collection interval.

    Time frame: Day 45 (maximum)

  6. Mass Balance Recovery of Total Radioactivity: Cum%Ae(Total)

    Cum%Ae(Total): cumulative amount of TR excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered. The radioactivity associated with toilet tissue was also determined, and the results were reported for each subject as a single value for the whole collection period only and included in the calculation of total Ae and % of dose recovered. The data reported for total calculations excluded toilet tissue data for the 0 - 6 hours post-dose to 0 - 456 hours post-dose collection intervals and included toilet tissue data for the 0 - 480 hours post-dose collection interval.

    Time frame: Day 45 (maximum)

Secondary outcomes

  1. AUC(0-tlast) of NT-814 (in plasma)

    AUC(0-tlast): Area under the curve from time 0 to the time of last measurable concentration.

    Time frame: Day 45 (maximum)

  2. AUC(0-tlast) of Total Radioactivity (in plasma and whole blood)

    AUC(0-tlast): Area under the curve from time 0 to the time of last measurable concentration.

    Time frame: Day 45 (maximum)

  3. Cmax of NT-814 (in plasma)

    Cmax: Maximum observed concentration.

    Time frame: Day 45 (maximum)

  4. Cmax of Total Radioactivity (in plasma and whole blood)

    Cmax: Maximum observed concentration.

    Time frame: Day 45 (maximum)

  5. Ae(urine) by interval

    Ae(urine): amount of TR excreted in urine.

    Time frame: Day 45 (maximum)

  6. %Ae(urine) by interval

    %Ae(urine): amount of TR excreted in urine expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  7. Ae(faeces) by interval

    Ae(faeces): amount of TR excreted in faeces.

    Time frame: Day 45 (maximum)

  8. %Ae(faeces) by interval

    %Ae(faeces): amount of TR excreted in faeces expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  9. Ae(total) by interval

    Ae(total): amount of TR excreted in urine and faeces combined.

    Time frame: Day 45 (maximum)

  10. %Ae(total) by interval

    %Ae(total): amount of TR excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  11. CumAe(urine) by interval

    CumAe(urine): cumulative amount of TR excreted in urine.

    Time frame: Day 45 (maximum)

  12. %CumAe(urine) by interval

    %CumAe(urine): cumulative amount of TR excreted in urine expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  13. CumAe(faeces) by interval

    CumAe(faeces): cumulative amount of TR excreted in faeces.

    Time frame: Day 45 (maximum)

  14. %CumAe(faeces) by interval

    %CumAe(faeces): cumulative amount of TR excreted in faeces expressed as a percentage of the radioactive dose administered.

    Time frame: Day 45 (maximum)

  15. CumAe(total) by interval

    CumAe(total): cumulative amount of TR excreted in urine and faeces combined. H=hour. The radioactivity associated with toilet tissue was also determined, and the results were reported for each subject as a single value for the whole collection period only and included in the calculation of total Ae and % of dose recovered. The data reported for total calculations excluded toilet tissue data for the 0 - 6 hours post-dose to 0 - 456 hours post-dose collection intervals and included toilet tissue data for the 0 - 480 hours post-dose collection interval.

    Time frame: Day 45 (maximum)

  16. %CumAe(total) by interval

    %CumAe(total): cumulative amount of TR excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered. H=hour. The radioactivity associated with toilet tissue was also determined, and the results were reported for each subject as a single value for the whole collection period only and included in the calculation of total Ae and % of dose recovered. The data reported for total calculations excluded toilet tissue data for the 0 - 6 hours post-dose to 0 - 456 hours post-dose collection intervals and included toilet tissue data for the 0 - 480 hours post-dose collection interval.

    Time frame: Day 45 (maximum)

  17. Evaluation of the extent of distribution of Total Radioactivity (TR) into blood cells

    Plasma concentration ratios for TR is reported.

    Time frame: Up to 45 days

  18. Number of subjects with treatment-emergent adverse events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation subject that does not necessarily have a causal relationship with treatment. Treatment-emergent AEs are AEs that commenced during/after the administration of investigational medicinal product (IMP) or commenced before administration of IMP (i.e., a pre-dose AE or existing medical condition) but worsened in intensity during exposure to IMP.

    Time frame: Up to 45 days

  19. Laboratory Evaluations - number of subjects with clinically important changes in hematology and clinical chemistry parameters from baseline

    Time frame: Baseline, 24 hours post-baseline and at Discharge

  20. Vital Signs - number of subjects with clinically important changes in systolic and diastolic blood pressure and heart rate from baseline

    Time frame: Baseline, 1 hour, 4 hours, 24 hours post-baseline and at Discharge

  21. Number of subjects with clinically relevant findings in electrocardiogram (ECG) parameters from baseline

    Time frame: Baseline, 1 hour, 4 hours, 24 hours post-baseline and at Discharge

  22. Number of subjects with clinically significant abnormal findings in physical examination

    Time frame: Up to 45 days

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 4, 2020
StartActual
Sep 30, 2020
Primary completionActual
Oct 29, 2020
CompletionActual
Oct 29, 2020
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04654897
Lead sponsor
Bayer
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
Sep 30, 2020
Primary completion
Oct 29, 2020
Completion
Oct 29, 2020
Last update
Oct 28, 2021

Study contacts

Prinicipal Investigator
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion